Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07277764 | Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)(REDEFINE) | recruiting | Phase 2 | 23 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Dec 5, 2025 |
| clinicaltrials |
| NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | recruiting | Phase 1 / Phase 2 | 202 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07254962 | CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)(CAPTURE) | not yet recruiting | Phase 2 | 75 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 26, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06839066 | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | recruiting | Phase 2 | 70 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07235566 | MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05783323 | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | recruiting | Phase 2 | 13 | Children's Hospital of PhiladelphiaOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03383094 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 2 | 126 | Loren Mell, MDOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06982300 | SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC(NACASOR) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05305131 | Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06509009 | Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | recruiting | Phase 2 | 208 | Ming-Yuan ChenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06374602 | Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | recruiting | Phase 2 | 20 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 60 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 30 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137039 | Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | not yet recruiting | Phase 2 | 34 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06688175 | IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | enrolling by invitation | Phase 2 | 32 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06970353 | Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06923826 | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)(TROP2) | recruiting | Phase 2 | 32 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06811844 | Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06987123 | TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial | not yet recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT06912711 | TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06861712 | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04875611 | Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment(NIVONASO-21) | recruiting | Phase 2 | 32 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05508347 | Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 170 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04517214 | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06892431 | JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer | not yet recruiting | Phase 2 | 150 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT03759431 | Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer(VOCAL) | active not recruiting | Phase 2 | 155 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 2 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06605131 | GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 72 | Sun Yat-sen UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 246 | Sun Yat-sen UniversityOTHER | 1 | Mar 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials